Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched
MA Holder Theramex Has Plans For More EU Countries
Executive Summary
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
You may also be interested in...
Gedeon Richter Spends Most On Biosimilar R&D
Hungary’s Gedeon Richter enjoyed “rapid sales growth” for its Terrosa teriparatide biosimilar in the first nine months of this year, justifying the firm’s continued advance into biosimilar development.
Ligand Set For Partnership Opportunities After Completing On Pfenex
Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.
Ligand Snaps Up Pfenex For Half A Billion
Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: